Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19

 Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19

Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19

Shots:

  • The IDMC has recommended stopping the enrollment in the P-III COMET-ICE trial due to evidence of profound efficacy. The study involves assessing VIR-7831 (GSK4182136) vs PBO in 583 patients for the early treatment of COVID-19 in adults at high risk of hospitalization
  • The results demonstrated an 85% reduction in hospitalization or death and were well tolerated. The ongoing trial will continue to be followed for 24wks.
  • Vir and GSK plan to submit a EUA to the FDA and for authorization in other countries. Additionally, the company also reported the results of new in vitro studies that indicate VIR-7831 maintains activity against major circulating COVID-19 variants

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Sharecast

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post